New stock news | Yino Well Medicine has submitted its application to the Hong Kong Stock Exchange for the third time

According to the disclosure from the Hong Kong Stock Exchange on July 16, Immvira Bioscience Inc. (referred to as Ynovia Pharmaceuticals) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors. According to the prospectus, Ynovia Pharmaceuticals is a clinical needs-oriented biotechnology company dedicated to the discovery, development, production, and commercialization of novel oncolytic immunotherapy and engineered exosome therapy. The company has established a product pipeline, including two oncolytic immunotherapy products targeting solid tumors, and five engineered exosome products with clinical application prospects or direct commercialization potential.